Scissortail Wealth Management LLC Takes Position in Aflac Incorporated (NYSE:AFL)

Scissortail Wealth Management LLC bought a new stake in shares of Aflac Incorporated (NYSE:AFL) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 7,634 shares of the financial services provider’s stock, valued at approximately $646,000.

Other institutional investors also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new position in shares of Aflac during the fourth quarter valued at approximately $25,000. CoreFirst Bank & Trust bought a new position in shares of Aflac during the fourth quarter valued at approximately $25,000. Studio Investment Management LLC bought a new position in shares of Aflac during the fourth quarter valued at approximately $27,000. Impact Partnership Wealth LLC grew its holdings in Aflac by 471.4% in the 3rd quarter. Impact Partnership Wealth LLC now owns 400 shares of the financial services provider’s stock worth $31,000 after buying an additional 330 shares in the last quarter. Finally, Bruce G. Allen Investments LLC bought a new position in Aflac in the 4th quarter worth approximately $32,000. 67.44% of the stock is owned by institutional investors.

Aflac Price Performance

Shares of NYSE:AFL traded up $0.16 on Wednesday, reaching $80.43. 2,114,324 shares of the company traded hands, compared to its average volume of 1,965,926. The company’s 50 day moving average is $82.03 and its 200-day moving average is $81.47. The stock has a market capitalization of $46.28 billion, a PE ratio of 10.38, a P/E/G ratio of 2.20 and a beta of 0.91. Aflac Incorporated has a fifty-two week low of $64.10 and a fifty-two week high of $86.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.06 and a quick ratio of 0.06.

Aflac (NYSE:AFL) last released its earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same quarter in the previous year, the company earned $1.29 EPS. As a group, analysts anticipate that Aflac Incorporated will post 6.41 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Kenny sold 5,000 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total value of $423,100.00. Following the completion of the sale, the director now owns 17,920 shares in the company, valued at $1,516,390.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Masatoshi Koide sold 30,493 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the sale, the director now directly owns 86,090 shares in the company, valued at $6,879,451.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Thomas J. Kenny sold 5,000 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total value of $423,100.00. Following the sale, the director now owns 17,920 shares of the company’s stock, valued at $1,516,390.40. The disclosure for this sale can be found here. Insiders sold 46,493 shares of company stock worth $3,765,706 over the last quarter. Corporate insiders own 0.80% of the company’s stock.

Analyst Upgrades and Downgrades

AFL has been the subject of a number of recent analyst reports. Morgan Stanley increased their price objective on Aflac from $80.00 to $84.00 and gave the stock an “equal weight” rating in a report on Monday. StockNews.com lowered Aflac from a “hold” rating to a “sell” rating in a report on Wednesday, April 10th. Keefe, Bruyette & Woods increased their price objective on Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a report on Wednesday, April 10th. Raymond James increased their price target on Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Finally, The Goldman Sachs Group increased their price target on Aflac from $61.00 to $75.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $82.15.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.